In GERD patients, mucosal repair associated genes are upregulated in non-inflamed oesophageal epithelium

D. R. de Vries a, *, J. J. M. Ter Linde a, M. A. van Herwaarden b, M. P. Schwartz c, P. Shephard d, M. M. Geng d, A. J. P. M. Smout a, M. Samsom a

a Department of Gastroenterology and Hepatology, University Medical Center, Utrecht, the Netherlands
b Department of Gastroenterology and Hepatology, Deventer Hospital, Deventer, the Netherlands
c Department of Gastroenterology and Hepatology, Meander Medical Center, Amersfoort, the Netherlands
d Nycomed Pharma AG, Konstanz, Germany

Received: October 13, 2008; Accepted: December 9, 2008

Abstract

Previous studies addressing the effects of acid reflux and PPI therapy on gene expression in oesophageal epithelium concentrated on inflamed tissue. We aimed to determine changes in gene expression in non-inflamed oesophageal epithelium of GERD patients. Therefore, we included 20 GERD patients with pathological total 24-hr acid exposure of 6–12% and SAP > 95%. Ten patients discontinued PPI treatment (PPI–), 10 took pantoprazole 40 mg bid (PPI+). Ten age/sex-matched healthy controls were recruited. Biopsies were taken from non-inflamed mucosa 6 cm and 16 cm proximal to the squamocolumnar junction (SCJ). Gene expression profiling of biopsies from 6 cm was performed on Human Genome U133 Plus 2.0 arrays (Affymetrix). Genes exhibiting a fold change >1.4 (t-test P-value < 1E–4) were considered differentially expressed. Results were confirmed by real-time RT-PCR. In PPI– patients, 92 microarray probesets were deregulated. The majority of the corresponding genes were associated with cell–cell contacts, cytoskeletal reorganization and cellular motility, suggesting facilitation of a migratory phenotype. Genes encoding proteins with anti-apoptotic or anti-proliferative functions or stress-protective functions were also deregulated. No probesets were deregulated in PPI+ patients. QPCR analysis of 20 selected genes confirmed most of the deregulations in PPI– patients, and showed several deregulated genes in PPI+ patients as well. In the biopsies taken at 16 cm QPCR revealed no deregulations of the selected genes. We conclude that upon acid exposure, oesophageal epithelial cells activate a process globally known as epithelial restitution: up-regulation of anti-apoptotic, anti-oxidant and migration associated genes. Possibly this process helps maintaining barrier function.

Keywords: gastroesophageal reflux disease, microarray expression profiling, epithelial restitution, oesophagus, oesophageal epithelial defense

Introduction

Gastroesophageal reflux disease (GERD) is very common in the western world with 10–20% of the population suffering from reflux symptoms at least weekly [1, 2]. Visible mucosal breaks in the oesophageal lining, facilitating access of refluxate to submucosal nociceptive nerve endings provide an accepted explanation for symptom generation in GERD patients with oesophagitis. However, a substantial number of patients with typical GERD symptoms does not show any macroscopic signs of damage to the oesophageal lining and can be classified as non-erosive reflux disease (NERD) patients. A recent report, investigating 999 subjects from the general population, showed that in subjects with daily reflux symptoms, prevalence of oesophagitis was only 35.6% [3]. In GERD patients with and without oesophagitis, visceral hypersensitivity has been demonstrated in non-inflamed areas [4]. This could be explained by central sensitization of nociceptive pathways [5]. Furthermore, epithelial cells under acid stress may secrete neuroinflammatory substances that can sensitize nociceptive nerve endings peripherally, and cause visceral hypersensitivity in GERD patients with and without oesophagitis [6].

Despite the fact that only a minority of GERD patients have oesophagitis, studies involving molecular analysis of oesophageal epithelium in GERD have, to date, focused mainly on inflamed tissue.
In inflamed mucosa, upregulation of cytokines and other pro-inflammatory gene products has been found, e.g. interleukin-8 (IL-8), cyclooxygenase-2 (Cox-2) and nuclear factor kappa B (NF-κB) [7–11]. Interestingly, Isomoto et al. found upregulated expression and increased content of IL-8 and NF-κB in non-inflamed oesophageal mucosal biopsies of NERD patients as well [12].

Inflammatory processes, however, are not the initial reaction of oesophageal epithelium to acid. Non-inflamed oesophageal epithelium possesses a number of defence mechanisms against acid. Inside the epithelial layer, structural and functional defences provide protection against damage by reflux, e.g. the different junctional complexes between cells (tight junctions (TJs), adhering junctions (AJs) and desmosomes), intercellular glycoconjugates with buffering properties and the epithelial transport proteins that regulate pH and buffering [13]. At a light microscopic level, macroscopically non-inflamed epithelium from GERD patients can display various characteristics, including submucosal papillary elongation, basal layer hyperplasia, infiltration of inflammatory cells, glycogenic acanthosis, hyperemia of the submucosan, thickening of the basement membrane and dilated intercellular spaces [14, 15].

The extent of acid exposure may affect the transcriptional response of the oesophageal epithelium. This assumption can be addressed by studying the effect of PPI therapy on transcription. So far, changes in mRNA expression resulting from PPI therapy have only been determined in oesophageal epithelium containing infiltrates of inflammatory cells [12, 11]. Furthermore, insight into the effect of the extent of acid exposure on mRNA expression may be gained by comparing proximal and distal transcription in the oesophageal epithelium to acid. Non-inflamed oesophageal lining decreases dramatically when a pH-probe is positioned more proximally in the oesophagus. This was shown in healthy volunteers and GERD patients [16, 17].

This study aimed, therefore, to investigate the influence of acid reflux on gene expression in non-inflamed oesophageal mucosa of GERD patients with pathological oesophageal acid exposure, using genome-wide mRNA expression analysis.

Ten patients discontinued any acid suppressing drugs for the duration of 2 weeks prior to endoscopy and sampling (PPI–). These patients were permitted to take antacids to alleviate unbearable symptoms with the exception of the 24 hrs directly preceding endoscopy. They marked their antacid use on a diary card. The remaining 10 patients were prescribed a fixed PPI dose for 2 weeks prior to upper GI-endoscopy (PPI +) (pantoprazole 40 mg bid) to ensure maximum acid suppression in this group. These patients were randomly assigned to either of the groups, in order of inclusion.

Healthy controls

An advertisement was placed in a local newspaper, and from the people who reacted 10 age- and sex-matched healthy controls free of gastrointestinal symptoms or a history of gastrointestinal disease were included. In conformity with their medical history, none of these subjects had undergone endoscopy before. Should a hiatal hernia or any lesions in the oesophagus, stomach or duodenum be found during upper GI endoscopy healthy controls were to be excluded.

Questionnaires

All patients completed a questionnaire assessing reflux symptoms (heartburn, regurgitation, retrosternal pain and belching) in the 2 weeks prior to endoscopy, modeled after the validated Nepean symptom score [18].

Sample collection

All subjects underwent oesophago-gastro-duodenoscopy, all endoscopies were performed by the same gastroenterologist. Six mucosal biopsies were collected at 6 and 16 cm proximal, respectively, from the squamocolumnar junction (SCJ) (reusable biopsy forceps, 2.2 mm oval cup with spike, Fujinon Medical Holland b.v., Veenendaal, The Netherlands). The biopsy samples were lifted from the forceps with a sterile hypodermic needle. Two biopsies from each location were placed in a sterile 2 ml microcentrifuge tube (Eppendorf, Germany), snap-frozen in liquid nitrogen and stored at –80°C until RNA extraction. The remaining two biopsies were fixated in formaldehyde solution for histopathologic evaluation.

Materials and methods

Patients

From the patients visiting the gastroenterology department at our hospital with recurrent heartburn, acid regurgitation and/or non cardiac chest pain, for at least 2 days per week, lasting 3 months or more, for whom diagnosis of GERD was established by 24-hrs oesophageal pH recording, 20 consecutive patients characterized by a total oesophageal acid exposure time between 6% and 12% were approached.

Patients with severe concomitant diseases, prior oesophageal or gastric surgery, oesophagitis C or D or Barrett’s oesophagus, peptic ulcer disease and comorbid conditions that might interfere with oesophageal or gastric motility including diabetes mellitus, systemic sclerosis and neurological disorders were non-eligible.

RNA extraction

Frozen biopsies were disrupted and homogenized with the Omni mH rotor-stator homogenizer in RLT buffer and subsequently total RNA was extracted using Qiagen RNasy microkit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Integrity of the samples was checked with the Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA) for distinct 18S and 28S rRNA peaks.

Microarray hybridization

RNA amplification and labelling

The RNA extracted from the biopsies acquired at 6 cm proximal to the SCJ were used for Affymetrix GeneChip hybridization. (Specifications in Appendix S1.)
RNA extracted from biopsies taken at both locations was used for QPCR expression analysis. QPCR reactions were performed using TaqMan® low-density arrays (LDAs) (Applied Biosystems, Foster City, CA, USA) using the ABI PRISM® 7900HT Sequence Detection System (AME Bioscience A/S, Norway). (Specifications in Appendix S1.)

Reference sample
A pooled reference cDNA sample was synthesized using 200 ng of RNA from five healthy controls for use in the normalization calculations, and profiled on the LDAs in the same session of runs as the rest of the samples.

Normalization of PCR data using housekeeping genes
To permit comparison between samples, several housekeeping genes were included in the low-density array to correct for variations in mRNA quality and quantity. These housekeeping genes were chosen after reviewing respective expression values as derived from the microarrays for several well-described housekeeping genes. The housekeeping genes we used were ACTB (beta actin), HMBS (hydroxymethylbilane synthase) and GAPDH (glyceraldehyde 3-phosphate dehydrogenase). These genes displayed a stepwise difference in expression level and were not differentially expressed between any of the groups. Housekeeping gene performance was further characterized using the M-value method with the Genorm software package (medgen.ugent.be/genorm) described by Vandesompele et al. [19].

Statistical analysis
Comparison of subject characteristics
Patient characteristics and questionnaire scores were compared between the two groups using Student's t-test or Chi-square tests as appropriate, considering a P-value of <0.05 statistically significant.

Computational analysis of microarray data
Affymetrix raw data (CEL files) were analyzed using the Gene Data Expressionist Pro software package in version 2.0 (Gene Data, Basel, Switzerland). (Specifications in Appendix S1.)

Table 1
Characteristics of healthy controls (HC), GERD patients off acid suppressive medication (PPI−) and GERD patients using maximum PPI dose (PPI+) 2 weeks prior to endoscopy

|       | N  | Male | Age    | Acid exposure (%) | Esophagitis (N) | Symptoms (all) | Heartburn, pain | Belching, regurgitation |
|-------|----|------|--------|------------------|-----------------|---------------|----------------|-----------------------|
| HC    | 10 | 5    | 49 (37–63) | N/A             | 0               | N/A           | N/A           | N/A                   |
| PPI−  | 10 | 6    | 46 (25–67) | 7.1 (5.7–9.9)   | 7               | 37 (12–57)    | 21 (4–32)     | 16 (0–27)             |
| PPI+  | 10 | 4    | 56 (36–75) | 9.3 (6.1–11.5)  | 4               | 21 (0–44)     | 10 (0–23)     | 11 (0–23)             |

Age, acid exposure and symptoms are displayed as mean (range). Symptom scores cover the 2 weeks prior to endoscopy and sample collection. N/A: not applicable. *P = 0.005; †P = 0.042; ‡P = 0.017.

Analysis of low-density array data
TaqMan® LDA results were analyzed with the SDS 2.2.1 software package using the 2\^-ΔΔCt method as described by Livak and Schmittgen [20]. The resulting relative quantities (RQs) were compared between groups using one-way analysis of variance (ANOVA) with Dunnett’s post-hoc tests. In comparing RQs a P-value of <0.05 was considered statistically significant and a P-value of <0.10 was considered a trend towards significance.

Results
Subjects
The characteristics of the patients and controls are shown in Table 1. A total of 14 healthy controls underwent endoscopy, four healthy controls were excluded upon finding abnormalities (2 grade A oesophagitis, 1 grade B oesophagitis, 1 Barrett’s epithelium).

Age and sex did not differ significantly between the healthy controls and both patient groups and between the patient groups. As expected, PPI− patients had more symptoms in total and especially more heartburn and retrosternal pain than the PPI+ group during the 2 weeks prior to biopsy collection. Regurgitation and belching, symptoms that are not treated by acid suppression, were equally prevalent in both patient groups. Oesophagitis prevalence did not differ between the PPI− and PPI+ groups. Histologic evaluation confirmed the absence of inflammation in all biopsy locations in all subjects. In three subjects from both patient groups, some infiltrating inflammatory cells were observed, however, in insufficient numbers to qualify as inflammation. Furthermore in some biopsy specimens stromal papillae were close to the mucosal surface, or mild glycogenic acanthosis was present. These findings were equally dispersed between the PPI− and the PPI+ groups. In the healthy controls group one biopsy showed mild glycogenic acanthosis and some lymphocytes.

Differentially expressed genes
Microarray mRNA expression profiling
The results from the microarray mRNA expression profiling are summarized in Table 2. The raw data are available as CEL files.
Table 2  Microarray results, GERD patients off PPI compared to healthy controls

| Gene             | Description of gene function                                    | Affymetrix probe set | Fold change |
|------------------|------------------------------------------------------------------|----------------------|------------|
| **Genes with functions in cytoskeletal rearrangements and cellular motility** |                                                                  |                      |            |
| ARF6             | ADP-ribosylation factor 6                                        | 214182_at            | 1.66       |
| ARFGEF1          | ADP-ribosylation factor guanine nucleotide-exchange factor 1 (brefeldin A-inhibited) | 216266_s_at          | 1.42       |
| MTPN             | Myotrophin                                                      | 223925_s_at          | 1.55       |
| NCKAP1           | NCK-associated protein 1                                        | 217465_at            | 1.62       |
| PLD1             | phospholipase D1, phosphatidylcholine-specific                   | 215723_s_at          | 1.40       |
| PPIKB1           | PTPRF interacting protein, binding protein 1 (liprin beta 1)    | 203736_s_at          | 1.45       |
| RPS6KB1          | ribosomal protein S6 kinase, 70 kDa, polypeptide 1              | 211578_s_at          | 1.46       |
| LOC729344        | similar to ribosomal protein S6 kinase, polypeptide 1           | 1556551_s_at         | 1.42       |
| SLC39A6          | solute carrier family 39 (zinc transporter), member 6           | 223925_s_at          | 1.55       |
| TUBGCP3          | tubulin, gamma complex associated protein 3                      | 203690_at            | 1.71       |
| WASF2            | WAS protein family, member 2                                     | 224563_at            | –1.43      |
| WASF4            | WAS protein family, member 4                                     | 40273_at             | 1.67       |
| LO0647909        | similar to WASP-family protein member 4                           | 1554726_at           | 1.49       |
| ZNF655           | zinc finger protein 655                                           | 1554726_at           | 1.49       |
| **Genes with functions in cell–cell contacts** |                                                                  |                      |            |
| BRMS1L           | breast cancer metastasis-suppressor 1-like                       | 224484_s_at          | 1.72       |
| MPP7             | membrane protein, palmitoylated 7 (MAGUK p55 subfamily member 7) | 1564308_a_at         | 1.60       |
| MYCBP2           | MYC binding protein 2                                             | 201960_s_at          | 1.56       |
| PVRL4            | poliovirus receptor-related 4                                    | 223540_at            | 1.44       |
| SPHK2            | sphingosine kinase 2                                             | 40273_at             | 1.67       |
| DBP              | D site of albumin promoter (albumin D-box) binding protein       | 224794_at            | 1.68       |
| **Genes with generic functions in epithelial restitution** |                                                                  |                      |            |
| ADSS             | adenylosuccinate synthase                                         | 221761_at            | 1.55       |
| CSNK1A1          | casein kinase 1, alpha 1                                          | 208866_at            | 1.49       |
| MAML3            | mastermind-like 3 (Drosophila)                                   | 242794_at            | 1.84       |
| **Genes with anti-apoptotic functions** |                                                                  |                      |            |
| AKAP1            | A kinase (PRKA) anchor protein 1                                  | 210625_s_at          | 1.51       |
| CSNK1A1          | casein kinase 1, alpha 1                                          | 208866_at            | 1.49       |
| ETFDH            | electron-transferring-flavoprotein dehydrogenase                 | 33494_at             | 1.49       |
| PPID             | peptidylprolyl isomerase D (cyclophilin D)                       | 205530_at            | 1.44       |
| MCL1             | myeloid cell leukemia sequence 1 (BCL2-related)                  | 214056_at            | 1.68       |
| RBMS1            | RNA binding motif, single stranded interacting protein 1         | 207266_x_at          | –1.48      |
| TANK             | TRAF family member-associated NFkB activator                     | 210458_s_at          | 1.65       |
| **Genes with anti-proliferative functions** |                                                                  |                      |            |
| BRMS1L           | breast cancer metastasis-suppressor 1-like                       | 224484_s_at          | 1.72       |
| DDX3X            | DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked               | 212515_s_at          | 1.43       |

Continued
| Gene     | Description of gene function                                                                 | Affymetrix probe set       | Fold change |
|----------|---------------------------------------------------------------------------------------------|----------------------------|-------------|
| IRF6     | interferon regulatory factor 6                                                              | 1552478_at                 | 1.49        |
| KPNB1    | karyopherin (importin) beta 1                                                               | 208975s_at                 | 1.65        |
|          |                                                                                             | 208974x_at                 | 1.64        |
|          |                                                                                             | 213507s_at                 | 1.45        |
| RPL29    | ribosomal protein L29                                                                        | 213969x_at                 | –1.44       |
|          |                                                                                             | 200823x_at                 | –1.46       |
| Genes with functions protective against oxidative stress |                                                                                        |                           |             |
| ALDH4A1  | aldehyde dehydrogenase 4 family, member A1                                                  | 203722_at                  | 1.51        |
| ALDH7A1  | Antiquitin; aldehyde dehydrogenase 7 family, member A1                                      | 208951_at                  | 1.49        |
| FAHD1    | fumarylacetoacetate hydrolase domain containing 1                                            | 227960_s_at                | 1.44        |
| HAGH     | hydroxyacylglutathione hydrolase                                                             |                           |             |
| Genes with aspecific or unknown functions |                                                                                         |                           |             |
| AGTPBP1  | ATP/GTP binding protein 1                                                                     | 204500_s_at                | 1.47        |
| ASNSD1   | asparagine synthetase domain containing 1                                                     | 217987_at                  | 1.54        |
| ATP5L    | ATP synthase, H+ transporting, mitochondrial F0 complex, subunit G                           | 207573x_at                 | –1.40       |
| UBE4A    | ubiquitination factor E4A (UFD2 homolog, yeast)                                             | 210453x_at                 | –1.47       |
|          |                                                                                             | 208746x_at                 | –1.49       |
| ATP8B1   | ATPase, Class I, type 8B, member 1                                                           | 214594x_at                 | 1.42        |
| ATRX     | alpha thalassemia/mental retardation syndrome X-linked (RAD54 homolog, S. cerevisiae)       | 208859_s_at                | 1.64        |
| LOC728849| similar to transcriptional regulator ATRX isoform 1                                            |                           |             |
| C10orf119| chromosome 10 open reading frame 119                                                         | 222464_s_at                | 1.66        |
| C12orf29 | chromosome 12 open reading frame 29                                                          | 213701_at                  | 1.85        |
| C14orf2  | chromosome 14 open reading frame 2                                                            | 210532_s_at                | –1.45       |
| CCDC47   | coiled-coil domain containing 47                                                             | 217814_at                  | 1.54        |
| CDV3     | CDV3 homolog (mouse)                                                                        | 213548_s_at                | 1.50        |
| COPA     | coatomer protein complex, subunit alpha                                                       | 208864_at                  | 1.56        |
| CTBS     | cathepsin B                                                                                 | 227961_at                  | 1.44        |
| DBT      | dihydrolipoamide branched chain transacylase E2                                              | 205371_s_at                | 1.59        |
| EIF3J    | eukaryotic translation initiation factor 3, subunit J                                       | 208985s_at                 | 1.46        |
| EIF4A2   | eukaryotic translation initiation factor 4A, isoform 2                                       | 1555996_s_at               | 1.70        |
| ELF1     | E74-like factor 1 (ets domain transcription factor)                                         | 233931_at                  | 1.47        |
| FASTKD5  | FAST kinase domains 5                                                                        | 219016_at                  | 1.46        |
| UBOX5    | U-box domain containing 5                                                                    |                           |             |
| GN65     | guanine nucleotide binding protein (G protein), gamma 5                                       | 207157_s_at                | –1.43       |
| CTBS     | guanine nucleotide binding protein-like 3 (nucleolar)-like                                  | 205010_at                  | 2.30        |
| GNL3L    | guanine nucleotide binding protein-like 3 (nucleolar)-like                                  | 212451_at                  | –1.58       |
| KIAA0256 | KIAA0256 gene product                                                                       | 213237_at                  | 1.44        |
| LOC400506| similar to TSG118.1                                                                         | 223849_s_at                | 1.40        |
| MOV10    | Mov10, Moloney leukemia virus 10, homolog (mouse)                                            | 207108_s_at                | 1.46        |
Table 2  Continued

| Gene         | Description of gene function                                                      | Affymetrix probe set | Fold change |
|--------------|-----------------------------------------------------------------------------------|----------------------|-------------|
| **PDE4DIP**  | phosphodiesterase 4D interacting protein (myomegalin) similar to phosphodiesterase 4D interacting protein isoform 2 | 214130_s_at          | 1.59        |
| **LOC727942**|                                                                                   |                      |             |
| **PITPNA**   | phosphotidylinositol transfer protein, alpha                                       | 201191_at            | 1.48        |
| **PRPF39**   | PRP39 pre-mRNA processing factor 39 homolog (yeast)                               | 220553_s_at          | 1.41        |
| **PURB**     | purine-rich element binding protein B                                              | 225120_at            | 1.52        |
| **RETSAT**   | retinol saturase (all-transretinol 13,14-reductase)                               | 1566472_s_at         | 1.40        |
| **RNF10**    | ring finger protein 10                                                            | 237062_at            | 1.68        |
| **RNMTL1**   | RNA methyltransferase like 1                                                     | 218993_at            | 1.46        |
| **RPE**      | ribulose-5-phosphate-3-epimerase                                                 | 216574_s_at          | 1.40        |
| **LOC649755**| similar to Ribulose-5-phosphate 3-epimerase (HUSSY-17)                            |                      |             |
| **RPL30**    | ribosomal protein L30                                                            | 200062_s_at          | –1.44       |
| **SNORA72**  | small nucleolar RNA, H/ACA box 72                                                |                      |             |
| **RPL37A**   | ribosomal protein L37a                                                           | 201429_s_at          | –1.41       |
| **RPS13**    | ribosomal protein S13                                                            |                      |             |
| **SNORD14A** | small nucleolar RNA, C/D box 14A                                                 | 200018_at            | –1.42       |
| **SNORD14B** | small nucleolar RNA, C/D box 14B                                                 |                      |             |
| **RPS18**    | ribosomal protein S18                                                            | 201049_s_at          | –1.40       |
| **RPS5-1033B10.18** | similar to ribosomal protein S18                                              |                      |             |
| **RPS24**    | ribosomal protein S24                                                            | 200061_s_at          | –1.46       |
| **RTF1**     | Rtf1, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae)          | 212302_at            | 1.56        |
| **SAMD8**    | sterile alpha motif domain containing 8                                          | 225950_at            | 1.87        |
| **SAPS3**    | SAPS domain family, member 3                                                     | 228105_at            | 1.62        |
| **SART3**    | squamous cell carcinoma antigen recognised by T cells 3                          | 209127_s_at          | 1.68        |
| **SH3RF2**   | SH3 domain containing ring finger 2                                              | 228892_at            | 1.47        |
| **SLAIN2**   | SLAIN motif family, member 2                                                     | 233230_s_at          | 1.47        |
| **SMARCAD1** | SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily a, containing DEAD/H box 1 | 223197_s_at          | 1.45        |
| **TCF25**    | transcription factor 25 (basic helix-loop-helix)                                 | 221495_s_at          | 1.44        |
| **TIMM8B**   | translocase inner mitochondrial membr. 8 homolog B (yeast)                       | 218357_s_at          | –1.41       |
| **TTF1**     | transcription termination factor, RNA polymerase I                               | 204772_s_at          | 1.53        |
| **USP24**    | ubiquitin specific protease 24                                                   | 212381_at            | 1.47        |
| **ZFYVE16**  | zinc finger, FYVE domain containing 16                                           | 203651_at            | 1.58        |
| **ZKSCAN1**  | zinc finger with KRAB and SCAN domains 1                                         | 1557953_at           | 1.50        |
| **ZNF33A**   | zinc finger protein 33a (KOX 31)                                                 | 231864_at            | 1.45        |
| **AK096729** |                                                                        | 1553979_at           | 1.45        |
| **AK092090** |                                                                        |                      |             |
| **BC015866** |                                                                        | 1555461_at           | 1.65        |

Results are arranged according to function, with the gene names in alphabetical order. For the sake of completeness, genes that have more than one function as represented in this table are mentioned more than once. Grey and white lines belong to different sets of results: either one gene was recognized by multiple probe sets, e.g. AKAP1, or one probe set could have recognized more than one gene, e.g. ATRX/LOC728849. In the case of ATP5L/UBE4A, two genes could both have been recognized by three probesets.
online at the NCBI Gene Expression Omnibus (GEO) page. Genes differentially expressed relative to healthy controls were found in the biopsies from PPI– patients, but no genes were significantly differentially expressed in the PPI+ patients. Among the differentially expressed genes, groups were discerned with functions that could be tied to cytoskeletal rearrangements and cellular motility or cell–cell contacts.

**Cytoskeletal rearrangements and cellular motility**

The cytoskeleton, consisting of actin, intermediate and tubulin filaments anchored to cell membrane and organelles, is a dynamic structure that enables cellular motion. Several genes with functions in modulating actin or tubulin towards increased cellular motility were found to be differentially expressed. The functions of these genes are specified in Appendix S1.

**Cell–cell contacts**

Migration is accompanied by changes in cell–cell contacts. Intercellular adhesion is mediated by junctional complexes, consisting of the apical tight junctions (TJs), essential for epithelial barrier function, the subapical adherens junctions (AJs) and the basolateral desmosomes. Junctional complexes are linked to cytoskeletal filaments. AJs have a critical role both as sensors of extracellular stimuli and in regulating the dynamics of epithelial cell layers. Several genes with functions in cell–cell contacts were deregulated, they are specified in Appendix S1.

**Epithelial restitution**

Cytoskeletal rearrangements, migration and regulation of intercellular adhesion can be linked to a process known as epithelial restitution. This is a repair mechanism whereby epithelial continuity is restored and barrier function maintained after superficial injury to the mucosa [21, 22]. During the process of restitution, cells bordering the zone of injury undergo junctional disassembly and flatten. This is viewed as a shift to a migratory phenotype driven by cytoskeletal rearrangements. The flattened migratory epithelial cells spread forward by extending pseudopod-like structures known as lamellipodia, thereby covering the defect in the epithelial layer. Subsequently, cell–cell contacts are re-established and normal cell shape and phenotype is retained. It has been shown that gap junctional intercellular communication is involved in gastric mucosal restitution following acid-induced injury [23]. Gap junctions are membrane-spanning channels composed of connexins that allow small signalling molecules to pass from cell to cell. Phosphorylation of connexins, mediated by one of the upregulated genes (CSNK1A1) [24], has been implicated in the regulation of gap junctional communication.

The MAML3 gene (mastermind-like 3) codes for a positive regulator of the Notch signalling pathway, which mediates cell–cell communications required for cell fate decisions [25].

Epithelial restitution is a highly energy-dependent process. This might explain the upregulation of adenylosuccinate synthetase (ADSS), an enzyme essential in ATP production. Accordingly, this enzyme was reported to be upregulated in the healing edges of epithelial wounds [26].

**Anti-apoptotic genes**

Epithelial restitution is independent of cell proliferation, cell survival however is essential. Several genes with anti-apoptotic functions were upregulated. This may ensure the survival of cells until epithelial restitution is completed.

The upregulated CSNK1A1 [27] and PPID [28] have anti-apoptotic effects, whereas the pro-apoptotic gene RBMS1 was downregulated [29]. AKAP1 targets protein kinase A to mitochondria, consequently PKA-dependent phosphorylation and thereby inactivation of proapoptotic protein BAD is increased and cell survival enhanced [30]. TANK has anti-apoptotic effects by modulating NF-κB activation [31, 32]. MCL1 is a gene of which the N-terminus determines its function: the protein product with the extended N-terminus has strong anti-apoptotic properties and a mild anti-proliferative effect, whereas the protein product with the N-terminal part deleted has a potent anti-proliferative effect whereas the anti-apoptotic function is less pronounced [33].

**Anti-proliferative genes**

Several genes with anti-proliferative and/or pro-differentiation properties were found. BRMS1L and DDX3X inhibit cell growth [34, 35], KPNB1 negatively regulates mitotic spindle formation [36, 37] and IRF6 keeps the cell in the G0 stage of the cell cycle, thus simultaneously promoting differentiation of the cell instead of proliferation [38]. In addition, downregulation of RPL29/HIP is associated with differentiation [39].

**Genes with protective roles against oxidative stress**

Excessive gastroesophageal reflux is associated with enhanced production of reactive oxygen species (ROS) [40]. Upregulation of ALDH4A1, which has the capacity to reduce ROS generation [41], may protect against reflux-induced oxidative stress. Peroxidation of membrane lipids is one of the mechanisms by which ROS lead to cell damage. Upregulation of ALDH7A1 and HAGH, which function in detoxification including lipid peroxidation products [42, 43], is expected to increase the survival chance of damaged cells.

Two other potentially interesting genes were upregulated with functions independent from epithelial restitution.

COPA encodes the α-subunit of the coatomer protein complex, involved in intracellular protein transport [44]. The N-terminal amino acids of α-COP are identical to xenin, a neurotensin receptor agonist. Xenin can be cleaved from α-COP by aspartic proteinases such as pepsin [45]. Interestingly, generation of xenin from its large precursor α-COP increases with acidic pH and exogenous administration of neurotensin reduces LES
pressure [46]. Xenin levels have not been quantified in the oesophagus to date.

ATP8B1 is a flippase, an enzyme active in restoring membrane symmetry [47], a process that may be involved in maintaining membrane integrity following superficial damage.

**TaqMan® low-density array validation**

Differential expression of 18 genes with putative functions in epithelial restitution was verified using QPCR. The selection of genes covers each of the different aspects of this process described above: cell–cell contacts (CSNK1A1, MAML3, PVRL4), cytoskeletal alterations and cellular motility (Abi-1, ARF6, MYCBP2, PFDN5, PPIF BP1, SLC39A6, SPHK2, TUBGCP3, WASF2), anti-apoptosis (AKAP1, CSNK1A1, MCL1, TANK), anti-proliferation (BRMS1L, KPNB1), and energy supply (ADSS). In addition, ALDH4A1 and COPA were included in the LDA setup.

Relative quantities of the transcripts are depicted as box plots with post-hoc test P-values in Fig. 1. Eleven genes showed significantly different mRNA expression levels between GERD patients off PPI relative to healthy controls and two genes showed a trend towards significance.

In contrast to the microarray results, in the PPI+ group nine genes were found to be differentially expressed as well, and one gene showed a trend towards significance. Most of the differences, however, were smaller than those in the PPI− group.

The gene MCL1 was represented by two assays on the LDA, because the affymetrix probe set for MCL1, which was detected as significantly different, recognizes two alternative gene products with different functions. Hs00172036_m1 measures the predominantly antiproliferative transcript without the N-terminal end, and Hs00766187_m1 measures the predominantly anti-apoptotic transcript with the N-terminal end intact. Only the latter was differentially expressed in the PPI+ group and showed a trend towards differential expression in the PPI− group.

In addition mRNA from the higher biopsy location, at 16 cm proximal to the SCJ, was subjected to LDA analysis, thereby investigating the expression levels of the selected genes in mucosa that had been exposed to substantially lower amounts of acid [16]. No differential expression of any of the 20 genes was, however, detected at this location in the oesophagus.
Discussion

The most important finding of the current study is that in GERD patients on and off PPI treatment, upregulated and downregulated genes were found with functions that inhibit apoptosis, prolong survival, promote differentiation and facilitate the loosening of intercellular contacts, thereby allowing the transformation into a migratory phenotype. This implies, that potential to counter damaging effects of excessive reflux is available in epithelial cells.

The findings of the current study suggest that the first defense of the oesophageal epithelium against excess acid reflux consists of only ultrastructural alterations and changes leading to an increased chance of cellular survival. No modifications of the mucosal defense that is already in place (i.e. the mucous layer, the intercellular matrix and the buffer capacity of cells and matrix components) could be deduced from the differentially expressed genes that were found. This does not necessarily mean that humoral defence mechanisms do not play a role in the first response to acid reflux, because the cells that secrete mucus and other buffering substances represent a minority of the epithelial layer. The underrepresentation of cells that secrete matrix components renders differences in mRNA levels in these cells between the investigated groups less likely to be detected.

Despite random assignment, the PPI− group had an average 2.2% less acid exposure than the PPI+ group, however, this difference is clinically irrelevant because both means are well above the 6% threshold that defines pathological reflux.

No significantly deregulated genes were found in the comparison of microarray results between healthy controls and PPI+ patients. In contrast, several of the genes selected for QPCR because of differential expression in PPI− patients relative to healthy controls turned out to be significantly deregulated in PPI+ patients as well. These changes in gene expression were, generally, less pronounced than those seen in the PPI− group. This result makes sense, biologically, because acid exposure is not reduced to zero in PPI− treated patients and other causative components of the refluxate are not targeted by PPIs.

No differences in the transcript levels of the genes selected for validation by QPCR were found in the biopsy specimens from the location that was 10 cm more proximal, 16 cm above the SCJ. Because acid exposure can be assumed to be approximately four times less at the proximal relative to the distal site [16], this suggests that the changes in mRNA expression we found are triggered when acid exposure exceeds a certain threshold. The findings of several studies in GERD patients with and without oesophagitis (erosive reflux disease (ERD) and non-erosive reflux disease (NERD)) show that reflux episodes that have a larger proximal extent are more likely to be perceived by the patient [48, 49]. Thus, the mechanisms for perception of these extensive reflux episodes appear to be independent of the gene expression response to acid we describe in the present study. A possible explanation is, that acid perception is primarily a neural response, and because the cell body of the primary afferent neuron is located outside the oesophagus, expression differences in these cells would be impossible to detect in the biopsies that were collected in the present study.

The biopsy specimens showed no signs of inflammation on histological evaluation, in patients with and without oesophagitis as well as in healthy controls. The explanation for this is that reflux oesophagitis is a well-demarcated condition, occurring just proximal to the oesophagogastric junction, rarely extending more than a few centimetres in the most severe cases, and these biopsies were taken at 6 and 16 cm proximal to the oesophagogastric junction.

In the RT-PCR validation results, ARF6 is downregulated and WASF2 is upregulated, opposite to the results of the microarray analysis. The TaqMan® probe for ARF6 has the extension s1, meaning that this probe recognizes a single-exon transcript, making it possible that part of the signal is generated by genomic DNA contaminating the original RNA sample [50]. The probe for WASF2 has the extension gH, signifying that this also potentially recognizes genomic DNA [50]. The original samples have been treated with DNase to remove any genomic DNA, minimizing the chance of DNA contamination, however, further validating experiments may be necessary to interpret the findings of the current study.

The epithelial restitution process has been described in oesophageal cells in vitro by Jimenez et al. [51, 52], however, despite attempts in several studies, it has not been observed in vivo in oesophageal epithelium to date [53]. The results from the present study, however, do indicate a role for epithelial restitution in the first response to excessive acid exposure of the oesophageal epithelium. The finding that so many genes that have anti-proliferative and anti-apoptotic functions were deregulated, in combination with the deregulation of genes that facilitate transition into a migratory phenotype are concordant with the two key events of the epithelial restitution process: cell survival and subsequent migration, in reaction to minor breaches in the epithelial continuity. The epithelial restitution process has been well characterized in intestinal columnar epithelium, however no events resembling epithelial restitution have been described in oesophageal epithelium to date. A possible explanation is that the oesophagus is lined with pseudostratified squamous epithelium, in which minor migratory movements are hard to discern, especially when no such concept has been postulated yet. Further studies in vitro and in vivo could clarify the phenotypic correlate of the gene expression changes we found.

No genes encoding cytokines, other pro-inflammatory substances or upregulators thereof were found to be differentially expressed in our patients. On the contrary, upregulation of the TANK gene which encodes a protein that inhibits NF-κB activation may exert an anti-inflammatory effect. At the AGA Digestive Disease Week of 2005, Yoshida et al. presented results of a microarray study conducted in NERD patients. They did report up-regulation of a wide variety of pro-inflammatory substances in the epithelial cells they had selectively studied with the help of laser capture microdissection [54]. However, this group did not confirm results with RT-PCR, and furthermore the biopsies studied by Yoshida et al. were taken closer to the squamocolumnar junction. Inflammatory infiltrates are present in a large portion of NERD patients’ oesophagus near the SCJ [55], and these infiltrating cells could have exerted an influence.
on gene expression in the epithelial cells. In another study using microarray expression profiling with the same arrays as were used in the present study, Ostrowski et al. compared biopsy specimens from non-inflamed oesophageal epithelium of NERD patients, patients with oesophagitis and patients with Barrett’s oesophagus. They found a distinct genetic signature for each of these patient groups. Unfortunately, no GERD-free controls were included in that study, which makes comparing their work to the current study difficult [56]. Furthermore, no 24-hrs pH-monitoring was included in the diagnostic work-up of the included subjects, possibly introducing phenotypical heterogeneity.

No upregulation of neuroinflammatory substances was detected. It can be hypothesized that protons, that are able to reach the nerve endings in the intra- and subcellular layer in larger amounts because of increased paracellular permeability, are the main mechanism for the heightened visceral sensitivity that has been found in GERD patients.

The COPA gene could not be confirmed by QPCR, however, this does not rule out xenin expression in the oesophagus, and a study design incorporating immunohistochemistry is needed to clarify this. It would also be interesting to further investigate the ATP8B1 gene, because no expression in the oesophagus of this important gene has been described thus far. The CEL files that have been made available online provide an excellent resource for researchers to verify the oesophageal expression of genes of their interest, and could instigate numerous new studies.

One could argue that the groups in the present study were relatively small, and that the results should be interpreted with caution. Two important preventive measures were taken, however, to maximize reliability: first, the detection thresholds for the microarray results were set to very strict levels, in order to ascertain that only significant expression differences would be detected. Second, RT-PCR analysis confirmed the majority of the found differences, providing a second measure of validity of the results. The current design was chosen to maximize results within the ethical and financial boundaries we faced, and was meant as a pilot work for future investigations.

Further studies are needed to investigate the epithelial restitution process in the oesophagus to clarify, for instance, the epithelial response in different groups of GERD patients, e.g. NERD patients or patients with severe oesophagitis or Barrett’s oesophagus, and to investigate whether these genetic changes can be tied to a morphologic correlate.

In conclusion, this study is the first to provide validated genome-wide expression data about non-inflamed oesophageal epithelium in GERD patients compared to healthy controls. The results point towards activation by acid reflux of the process we know as epithelial restitution, which has not been described before in the oesophagus.

Supporting Information

Additional Supporting Information may be found in the online version of this article.

Appendix S1 Methods and results

This material is available as part of the online article from: http://www.blackwell-synergy.com/doi/abs/10.1111/j.1582-4934.2008.00626.x
(This link will take you to the article abstract).

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.

Conflict of Interest

This work was partially funded by Nycomed Pharma AG, Konstanz, Germany. P Shephard and MM Geng were members of the research staff at Nycomed Pharma AG at the time of the conceptualization and data collection of the study. No conflicts of interest exist for DR de Vries, JJM ter Linde, MA van Herwaarden, MP Schwartz, AJPM Smout and M Samsom.

References

1. Camilleri M, Dubois D, Coulie B, Jones M, Kahrilas PJ, Rentz AM, Sonnenberg A, Stanghellini V, Stewart WF, Tack J, Talley NJ, Whitehead W, Revicki DA. Prevalence and socio-economic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol. 2005; 3: 543–52.
2. Dent J, El Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005; 54: 710–7.
3. Ronkainen J, Aro P, Storskrubb T, Lind T, Bolling-Stormalv E, Junghard O, Talley NJ, Agreus L. Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population – the Kalixanda study. Aliment Pharmacol Ther. 2006; 23: 1725–33.
4. Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut. 1995; 37: 7–12.
5. Fass R, Naliboff B, Higa L, Johnson C, Kodner A, Munakata J, Ngo J, Mayer EA. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology. 1998; 115: 1363–73.
6. Holzer P. Sensory neurone responses to mucosal noxae in the upper gut: relevance to mucosal integrity and gastrointestinal...
pain. Neurogastroent Motil. 2002; 14: 459–75.
7. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, Saeed IT, Burnham WR, Farthing MJG. Diversity in the oesophageal phenotypic response to gastro-esophageal reflux: immunological determinants. Gut. 2002; 50: 451–9.
8. Hamoui N, Peters JH, Schneider S, Uchida K, Yang DY, Valboehmer D, Hagen JA, DeMeester SR, DeMeester TR, Danenberg K, Danenberg P. Increased acid exposure in patients with gastroesophageal reflux disease influences cyclooxygenase-2 gene expression in the squamous epithelium of the lower esophagus. Arch Surg. 2004; 139: 712–7.
9. Matthews P, Aziz Q, Facer P, Davis J, Thompson D, Anand P. Increased expression of the capsaicin receptor TRPV1 in the inflamed human esophagus. Gastroenterology. 2004; 126: A427.
10. Souza RF, Shewmake KL, Shen Y, Ramirez RD, Bullock JS, Hladik CL, Lee EL, Terada LS, Spechler SJ. Differences in ERK activation in squamous mucosa in patients who have gastroesophageal reflux disease with and without Barrett's esophagus. Am J Gastroenterol. 2005; 100: 551–9.
11. Yoshida N, Uchiyama K, Kuroda M, Sakuma K, Kokura S, Ichikawa H, Naito M, Nishi Y, Ohtsuru A, Inoue K, Akazawa Y, Arai T, Tanaka Y, Mafune K. Enhanced expression of interleukin-8 in the esophageal squamous epithelium in patients with reflux disease. Scand J Gastroenterol. 2004; 39: 816–22.
12. Isomoto H, Saenko VA, Kanazawa Y, Nishi Y, Ohtsuru A, Inoue K, Akazawa Y, Takeshima F, Omagari K, Miyazaki M, Mizuta Y, Murata I, Yamashita S, Kohno S. Enhanced expression of interleukin-8 and activation of nuclear factor kappa-B in endoscopic-negative gastroesophageal reflux disease. Am J Gastroenterol. 2004; 99: 589–97.
13. Orlando RC. Oesophageal mucosal resistance. Aliment Pharmacol Ther. 1998; 12: 191–7.
14. Takubo K, Homma N, Aroyl G, Sawabe M, Arai T, Tanaka Y, Mafune K. Is there a set of histologic changes that are invariably reflux associated? Arch Pathol Lab Med. 2005; 129: 159–63.
15. Vieth M, Fiocca R, Haringisma J, Delarive J, Wiesel PH, Tam W, Tytgat GNJ, Dent J, Edebo A, Lundell L, Stolte M. Radial distribution of dilated intercellular spaces of the esophageal squamous epithelium in patients with reflux disease exhibiting discrete endoscopic lesions. Digest Dis. 2004; 22: 208–12.
16. Weusten B, Akkermans L, vanBerge-Henegouwen G, Smout A. Symptom perception in gastroesophageal reflux disease is dependent on spatiotemporal reflux characteristics. Gastroenterology. 1999; 108: 1739–44.
17. Weusten BL, Akkermans LM, vanBerge-Henegouwen GP, Smout AJ. Spatiotemporal characteristics of physiologic gastroesophageal reflux. Am J Physiol Gastrointest Liver Physiol. 1994; 266: G367–62.
18. Tenney NJ, Verlinden M, Jones M. Validity of a new quality of life scale for functional dyspnea: a United States multicenter trial of the Nepean Dyspnea Index. Am J Gastroenterol. 1999; 94: 2390–7.
19. Vandemospele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speelman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3: RESEARCH0034.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative RT-PCR. Methods. 2001; 25: 402–8.
21. Mammen JM, Matthews JB. Mucosal repair in the gastrointestinal tract. Crit Care Med. 2003; 31: S532–7.
22. Lacy ER, Ito S. Rapid epithelial restitution of the rat gastric mucosa after ethanol injury. Lab Invest. 1984; 51: 573–83.
23. Takahashi N, Joh T, Yokoyama Y, Seno K, Nomura T, Ohara H, Ueda F, Itoh M. Importance of gap junction in gastric mucosal restitution from acid-induced injury. J Lab Clin Med. 2000; 136: 93–9.
24. Solan JL, Lampe PD. Connexin phosphorylation as a regulatory event linked to gap junction channel assembly. Biochim Biophys Acta. 2005; 1711: 154–63.
25. Lin SE, Oyama T, Nagase T, Harigaya K, Kitagawa M. Identification of new human mastermind proteins defines a family that consists of positive regulators for notch signaling. J Biol Chem. 2002; 277: 50612–20.
26. Gassmann MG, Stanzel A, Werner S. Growth factor-regulated expression of enzymes involved in nucleotide biosynthesis: a novel mechanism of growth factor action. Oncogene. 1999; 18: 6676–77.
27. Izerdjene K, Douglas L, Delaney AB, Houghton JA. Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex. Cancer Res. 2004; 64: 8036–44.
28. Machida K, Ohta Y, Osada H. Suppression of apoptosis by cyclophilin D via stabilization of hexokinase II mitochondrial binding in cancer cells. J Biol Chem. 2006; 281: 14314–20.
29. Nomura J, Matsumoto K, Iguchi-Arima SM, Ariga H. Mitochondria-independent induction of Fas-mediated apoptosis by MSSI. Oncol Rep. 2006; 14: 1305–9.
30. Affaitati A, Cardone L, De CT, Carlucci A, Ginsberg MD, Varrone S, Gottesman ME, Avvedimento EV, Feliciello A. Essential role of A-kinase anchor protein 121 for cAMP signaling to mitochondria. J Biol Chem. 2003; 278: 4286–94.
31. Pomerantz JL, Baltimore D. NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J. 1999; 18: 6694–704.
32. Rothe M, Xiong J, Shu HB, Williamson K, Godard A, Goeddel DV. I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction. Proc Natl Acad Sci USA 1999; 96: 8241–6.
33. Germain M, Duronio V. The N terminus of the anti-apoptotic BCL-2 homologue MCL-1 regulates its localization and function. J Biol Chem. 2007; 282: 32233–42.
34. Chao CH, Chen CM, Cheng PL, Shih JW, Tsou AP, Lee YH, DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waft1/cip1 promoter, is a candidate tumor suppressor. Cancer Res. 2006; 66: 6579–88.
35. Nikolsaev AV, Papanikolau NA, Li M, Qin J, Gu W. Identification of a novel BRM51-homologue protein p40 as a component of the mSin3A/p33(ING1b)/HDAC1 deacetylase complex. Biochem Biophys Res Commun. 2004; 323: 1216–22.
36. Harel A, Forbes DJ. Importin beta: conducting a much larger cellular symphony. Mol Cell. 2004; 16: 319–30.
37. Tahara K, Takagi M, Ohsugi M, Sone T, Nishiumi F, Maeshima K, Horiuichi Y, Tokai-Nishizumi N, Imamoto F, Yamamoto T, Kose S, Imamoto N. Importin-beta and the small guanosine triphosphatase Ran mediate chromosome loading of the human chromokinesin Kid. J Cell Biol. 2008; 180: 493–506.
the proteasome in a cell cycle-dependent manner. Mol Cell Biol. 2008; 28: 2235–43.

39. Miller SA, Brown AJ, Farach-Carson MC, Kim-Safram CB. HIP/RPL29 down-regulation accompanies terminal chondrocyte differentiation. Differentiation. 2003; 71: 322–36.

40. Wetscher GJ, Hinder RA, Bagchi D, Hinder PR, Bagchi M, Perdikis G, McGinn T. Reflux esophagitis in humans is mediated by oxygen-derived free radicals. Am J Surg. 1995; 170: 552–6.

41. Yoon KA, Nakamura Y, Arakawa H. Identification of ALDH4 as a p53-inducible gene and its protective role in cellular stresses. J Hum Genet. 2004; 49: 134–40.

42. Vasiliou V, Pappa A, Estey T. Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. Drug Metab Rev. 2004; 36: 279–99.

43. Thornalley PJ. Glyoxalase I–structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans. 2003; 31: 1343–8.

44. Schroder-Kohne S, Letourneur F, Riezman H. Alpha-COP can discriminate between distinct, functional di-lysine signals in vitro and regulates access into retrograde transport. J Cell Sci. 1998; 111: 3459–70.

45. Feurle GE. Xenin—a review. Peptides. 1998; 19: 609–15.

46. Theodorsson-Norheim E, Thor K, Rosell S. Relation between lower esophageal sphincter (LES) pressure and the plasma concentration of neurotensin during intravenous infusion of neurotensin(1-13) and (Gln4)neurotensin(1-13) in man. Acta Physiol Scand Suppl. 1983; 515: 29–35.

47. Paulusma CC, Folmer DE, Ho-Mok KS, de Waart DR, Hiliarius PM, Verhoeven AJ, Oude Elferink RP. ATP8B1 requires an accessory protein for endoplasmic reticulum exit and plasma membrane lipid flippase activity. Hepatology. 2008; 47: 268–78.

48. Bredenoord AJ, Weusten BLAM, Curvers WL, Timmer R, Smout AJPM. Determinants of perception of heartburn and regurgitation. Gut. 2006; 55: 313–8.

49. Schey R, Shapiro M, Navarro-Rodriguez T, Fass SS, Han B, Wendel C, Fass R. Comparison of the different characteristics of sensed reflux events among different heartburn groups. J Clin Gastroenterol. 2008; doi:10.1097/MCG.0b013e318182673f.

50. Lazarak K, Wang Y, Zhong J, Malchenko S, Rabkin S, Hunkapiller K, Furtado N, Petrauskene O, Guegler K, Gilbert E, Spier E. The design process for a new generation of quantitative gene expression analysis tools – TaqMan® probe-based assays for human and other model organism genes. Appl Biosyst. 2006.

51. Jimenez P, Lanas A, Piazuelo E, Esteva F. Effect of growth factors and prostaglandin E2 on restitution and proliferation of rabbit esophageal epithelial cells. Dig Dis Sci. 1998; 43: 2309–16.

52. Jimenez P, Lanas A, Piazuelo E, Esteva F. Effects of extracellular pH on restitution and proliferation of rabbit oesophageal epithelial cells. Aliment Pharmacol Ther. 1999; 13: 545–52.

53. Tobey NA, Powell DW, Schreiner VJ, Orlando RC. Serosal bicarbonate protects against acid injury to rabbit esophagus. Gastroenterology. 1989; 96: 1466–77.

54. Yoshida N, Kuroda M, Uchiyama K, Suzuki T, Okuda T, Tuboi H, Kajikawa H, Handa O, Koura S, Ichikawa H, Naito Y, Yoshikawa T, Okanoue T. Microarray analysis of transcriptome in patients with non-erosive reflux disease. Gastroenterology. 2005; 128: A1–A821.

55. Zhou YH, rodsman V, Mastracci L, Spaggiari P, Dulbecco P, Ceppa P, Savarino E, Parodi A, Mansi C, Fiocca R. Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. Am J Gastroenterol. 2005; 100: 2299–306.

56. Ostrowski J, Rubel T, Wyrwicz LS, Mikula M, Bielasik A, Butruk E, Regula J. Three clinical variants of gastroesophageal reflux disease form two distinct gene expression signatures. J Mol Med. 2006; 84: 872–82.